Cargando…

Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives

ABSTRACT: The spread of multi-drug-resistant bacterial strains causing serious infectious diseases dictates the development of new approaches to combat these diseases. In addition to drug resistance, the important causative agent of tuberculosis (Mycobacterium tuberculosis (Mtb)) is able to persist...

Descripción completa

Detalles Bibliográficos
Autores principales: Shleeva, Margarita, Savitsky, Alexander, Kaprelyants, Arseny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126513/
https://www.ncbi.nlm.nih.gov/pubmed/33997929
http://dx.doi.org/10.1007/s00253-021-11349-0
_version_ 1783693775237808128
author Shleeva, Margarita
Savitsky, Alexander
Kaprelyants, Arseny
author_facet Shleeva, Margarita
Savitsky, Alexander
Kaprelyants, Arseny
author_sort Shleeva, Margarita
collection PubMed
description ABSTRACT: The spread of multi-drug-resistant bacterial strains causing serious infectious diseases dictates the development of new approaches to combat these diseases. In addition to drug resistance, the important causative agent of tuberculosis (Mycobacterium tuberculosis (Mtb)) is able to persist asymptomatically in individuals for many years, causing latent forms of tuberculosis. In such a dormant state, Mtb cells are also resistant to known antibiotics. In this regard, photodynamic inactivation (PDI) could be an effective alternative to antibiotics as its action is based on the generation of active forms of oxygen independently on the presence of specific antibiotic targets, thereby inactivating both drug-resistant and dormant bacteria. In this review, we summarise examples of the application of PDI for the elimination of representatives of the genus Mycobacteria, both in vitro and in vivo. According to published results, including photosensitisers in the PDI regime results in a significantly higher lethal effect. Such experiments were mainly performed using chemically synthesised photosensitisers, which need to be transported to the areas of bacterial infections, limiting PDI usage by surface (skin) diseases. In this regard, endogenous photosensitisers (mainly porphyrins) could be used to solve the problem of transportation. In vitro experiments demonstrate the effective application of PDI for mycobacteria, including Mtb, using endogenous porphyrins; the intracellular contents of these substances can be elevated by administration of 5-aminolevulenic acid, a precursor of porphyrin synthesis. Photodynamic inactivation can also be used for dormant mycobacteria, which are characterised by high levels of endogenous porphyrins. Thus, PDI can effectively eliminate drug-resistant mycobacteria. The exploitation of modern light-transmitting techniques opens new possibilities to use PDI in clinical settings. KEY POINTS: •The potential effects of photodynamic inactivation of mycobacteria are critically reviewed. •Approaches to photoinactivation of mycobacteria using exogenous and endogenous photosensitisers are described. •Prospects for the use of photodynamic inactivation in the treatment of tuberculosis are discussed.
format Online
Article
Text
id pubmed-8126513
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81265132021-05-17 Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives Shleeva, Margarita Savitsky, Alexander Kaprelyants, Arseny Appl Microbiol Biotechnol Mini-Review ABSTRACT: The spread of multi-drug-resistant bacterial strains causing serious infectious diseases dictates the development of new approaches to combat these diseases. In addition to drug resistance, the important causative agent of tuberculosis (Mycobacterium tuberculosis (Mtb)) is able to persist asymptomatically in individuals for many years, causing latent forms of tuberculosis. In such a dormant state, Mtb cells are also resistant to known antibiotics. In this regard, photodynamic inactivation (PDI) could be an effective alternative to antibiotics as its action is based on the generation of active forms of oxygen independently on the presence of specific antibiotic targets, thereby inactivating both drug-resistant and dormant bacteria. In this review, we summarise examples of the application of PDI for the elimination of representatives of the genus Mycobacteria, both in vitro and in vivo. According to published results, including photosensitisers in the PDI regime results in a significantly higher lethal effect. Such experiments were mainly performed using chemically synthesised photosensitisers, which need to be transported to the areas of bacterial infections, limiting PDI usage by surface (skin) diseases. In this regard, endogenous photosensitisers (mainly porphyrins) could be used to solve the problem of transportation. In vitro experiments demonstrate the effective application of PDI for mycobacteria, including Mtb, using endogenous porphyrins; the intracellular contents of these substances can be elevated by administration of 5-aminolevulenic acid, a precursor of porphyrin synthesis. Photodynamic inactivation can also be used for dormant mycobacteria, which are characterised by high levels of endogenous porphyrins. Thus, PDI can effectively eliminate drug-resistant mycobacteria. The exploitation of modern light-transmitting techniques opens new possibilities to use PDI in clinical settings. KEY POINTS: •The potential effects of photodynamic inactivation of mycobacteria are critically reviewed. •Approaches to photoinactivation of mycobacteria using exogenous and endogenous photosensitisers are described. •Prospects for the use of photodynamic inactivation in the treatment of tuberculosis are discussed. Springer Berlin Heidelberg 2021-05-17 2021 /pmc/articles/PMC8126513/ /pubmed/33997929 http://dx.doi.org/10.1007/s00253-021-11349-0 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Mini-Review
Shleeva, Margarita
Savitsky, Alexander
Kaprelyants, Arseny
Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
title Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
title_full Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
title_fullStr Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
title_full_unstemmed Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
title_short Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
title_sort photoinactivation of mycobacteria to combat infection diseases: current state and perspectives
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126513/
https://www.ncbi.nlm.nih.gov/pubmed/33997929
http://dx.doi.org/10.1007/s00253-021-11349-0
work_keys_str_mv AT shleevamargarita photoinactivationofmycobacteriatocombatinfectiondiseasescurrentstateandperspectives
AT savitskyalexander photoinactivationofmycobacteriatocombatinfectiondiseasescurrentstateandperspectives
AT kaprelyantsarseny photoinactivationofmycobacteriatocombatinfectiondiseasescurrentstateandperspectives